COVID-19 中的血栓风险：一项病例系列和病例对照研究。
Thrombotic risk in COVID-19: a case series and case-control study.
机构信息
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK and Brighton and Sussex Medical School, Falmer, UK
Brighton and Sussex Medical School, Brighton, UK and Royal Sussex County Hospital, Brighton, UK.
出版信息
Clin Med (Lond). 2020 Jul;20(4):e76-e81. doi: 10.7861/clinmed.2020-0228. Epub 2020 May 18.
Abstract
BACKGROUND
A possible association between COVID-19 infection and thrombosis, either as a direct consequence of the virus or as a complication of inflammation, is emerging in the literature. Data on the incidence of venous thromboembolism (VTE) are extremely limited.
METHODS
We describe three cases of thromboembolism refractory to heparin treatment, the incidence of VTE in an inpatient cohort, and a case-control study to identify risk factors associated with VTE.
RESULTS
We identified 274 confirmed (208) or probable (66) COVID-19 patients. 21 (7.7%) were diagnosed with VTE. D-dimer was elevated in both cases (confirmed VTE) and controls (no confirmed VTE) but higher levels were seen in confirmed VTE cases (4.1 vs 1.2 μg/mL, p<0.001).
CONCLUSION
Incidence of VTE is high in patients hospitalised with COVID-19. Urgent clinical trials are needed to evaluate the role of anticoagulation in COVID-19. Monitoring of D-dimer and anti-factor Xa levels may be beneficial in guiding management.
摘要
背景
COVID-19 感染与血栓之间可能存在关联，这种关联可能是病毒的直接后果，也可能是炎症的并发症。文献中出现了这种关联的相关数据。静脉血栓栓塞症（VTE）的发病率数据极其有限。
方法
我们描述了三例肝素治疗无效的血栓栓塞病例，住院患者队列中的 VTE 发病率，以及一项病例对照研究，以确定与 VTE 相关的危险因素。
结果
我们确定了 274 例确诊（208 例）或可能（66 例）COVID-19 患者。21 例（7.7%）被诊断为 VTE。两种情况下 D-二聚体均升高（确诊 VTE 组和对照组），但确诊 VTE 组的水平更高（4.1μg/ml 比 1.2μg/ml，p<0.001）。
结论
COVID-19 住院患者的 VTE 发病率较高。迫切需要进行临床试验来评估抗凝在 COVID-19 中的作用。监测 D-二聚体和抗因子 Xa 水平可能有助于指导治疗。
相似文献
1
Thrombotic risk in COVID-19: a case series and case-control study.COVID-19 中的血栓风险：一项病例系列和病例对照研究。
Clin Med (Lond). 2020 Jul;20(4):e76-e81. doi: 10.7861/clinmed.2020-0228. Epub 2020 May 18.
2
Research in brief: Coagulopathy in COVID-19: Determining and managing thrombotic risk in COVID-19 infection.简要研究：新型冠状病毒肺炎中的凝血功能障碍：确定和管理新型冠状病毒肺炎感染中的血栓形成风险
Clin Med (Lond). 2020 Jul;20(4):e59. doi: 10.7861/clinmed.rib.20.4.2.
3
Incidence of venous thromboembolism in hospitalized patients with COVID-19.COVID-19 住院患者静脉血栓栓塞症的发生率。
J Thromb Haemost. 2020 Aug;18(8):1995-2002. doi: 10.1111/jth.14888. Epub 2020 Jul 27.
4
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.COVID-19 患者接受抗栓治疗时的静脉血栓栓塞症的系统评估：发生率和 D-二聚体作为预测因素的作用。
J Thromb Thrombolysis. 2020 Jul;50(1):211-216. doi: 10.1007/s11239-020-02146-z.
5
Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis.评估 COVID-19 和细菌性肺炎患者 D-二聚体水平的变化：一项回顾性分析。
J Thromb Thrombolysis. 2020 Oct;50(3):548-557. doi: 10.1007/s11239-020-02171-y.
6
Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19.COVID-19 全人群前瞻性队列中静脉血栓栓塞症的发生率。
J Thromb Thrombolysis. 2020 Oct;50(3):558-566. doi: 10.1007/s11239-020-02202-8.
7
Venous thromboembolism and COVID-19.静脉血栓栓塞与2019冠状病毒病
Respir Med Res. 2020 Nov;78:100759. doi: 10.1016/j.resmer.2020.100759. Epub 2020 Apr 28.
8
Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease 2019.2019年冠状病毒病住院患者D-二聚体水平的变化趋势及诊断价值
Medicine (Baltimore). 2020 Nov 13;99(46):e23186. doi: 10.1097/MD.0000000000023186.
9
Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.新型冠状病毒肺炎重型患者静脉血栓栓塞症发病情况。
J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6.
10
Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?COVID-19 相关静脉血栓栓塞症：目前我们了解多少？
Acta Haematol. 2020;143(5):417-424. doi: 10.1159/000508233. Epub 2020 May 12.
引用本文的文献
1
Prevalence of Thromboembolic Events, Including Venous Thromboembolism and Arterial Thrombosis, in Patients with COVID-19: A Systematic Review with Meta-Analysis.2019冠状病毒病患者血栓栓塞事件（包括静脉血栓栓塞和动脉血栓形成）的患病率：一项系统评价与荟萃分析
J Tehran Heart Cent. 2023 Jul;18(3):154-169. doi: 10.18502/jthc.v18i3.14110.
2
Novel inflammatory markers in patients with severe COVID-19 and a pulmonary thrombotic event.患有重症新型冠状病毒肺炎（COVID-19）并发生肺血栓形成事件患者的新型炎症标志物。
Cent Eur J Immunol. 2023;48(3):167-173. doi: 10.5114/ceji.2023.131382. Epub 2023 Sep 21.
3
Exploring heterogeneity in reported venous thromboembolism risk in COVID-19 and comparison to other viral pneumonias: a systematic review and meta-regression.探索COVID-19报告的静脉血栓栓塞风险的异质性并与其他病毒性肺炎进行比较：一项系统综述和Meta回归分析
Res Pract Thromb Haemost. 2023 Jul 13;7(5):102146. doi: 10.1016/j.rpth.2023.102146. eCollection 2023 Jul.
4
Pulmonary Thrombosis despite Therapeutic Anticoagulation in COVID-19 Pneumonia: A Case Report and Literature Review.COVID-19 肺炎治疗性抗凝后发生肺血栓栓塞症：病例报告及文献复习。
Viruses. 2023 Jul 12;15(7):1535. doi: 10.3390/v15071535.
5
Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital.调查纳马齐教学医院新冠肺炎患者肺栓塞的患病率、预测因素和风险因素。
Blood Res. 2023 Sep 30;58(3):127-132. doi: 10.5045/br.2023.2023076. Epub 2023 Jul 11.
6
Pathophysiological effects of SARS-CoV-2 infection on the cardiovascular system and its clinical manifestations-a mini review.新型冠状病毒2019感染对心血管系统的病理生理影响及其临床表现——一篇综述
Front Cardiovasc Med. 2023 May 16;10:1162837. doi: 10.3389/fcvm.2023.1162837. eCollection 2023.
7
The analysis of Fe-dependent serum enzymes in severe COVID-19 with a pulmonary thrombotic event.伴有肺血栓形成事件的重症新型冠状病毒肺炎中与铁相关的血清酶分析。
Cent Eur J Immunol. 2022;47(4):293-298. doi: 10.5114/ceji.2022.124076. Epub 2023 Jan 13.
8
Associations between SARS-CoV-2 infections and thrombotic complications necessitating surgical intervention: A systematic review.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染与需要手术干预的血栓形成并发症之间的关联：一项系统综述。
World J Methodol. 2022 Nov 20;12(6):476-487. doi: 10.5662/wjm.v12.i6.476.
9
Thromboembolic Disease and Cardiac Thrombotic Complication in COVID-19: A Systematic Review.COVID-19中的血栓栓塞性疾病和心脏血栓并发症：一项系统评价
Metabolites. 2022 Sep 22;12(10):889. doi: 10.3390/metabo12100889.
10
A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: A communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH.对预测COVID-19住院患者静脉血栓栓塞的生物标志物的系统评价：来自国际血栓与止血学会（ISTH）预测与诊断变量科学与标准化委员会的交流
Res Pract Thromb Haemost. 2022 Aug 26;6(6):e12786. doi: 10.1002/rth2.12786. eCollection 2022 Aug.
本文引用的文献
1
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.COVID-19 重症监护病房危重症患者的血栓并发症发生率。
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
2
Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.与 2019 年冠状病毒病（COVID-19）严重疾病和死亡相关的血液学、生物化学和免疫生物标志物异常：荟萃分析。
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028. doi: 10.1515/cclm-2020-0369.
3
Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.新型冠状病毒肺炎重型患者静脉血栓栓塞症发病情况。
J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6.
4
Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.组织型纤溶酶原激活物（tPA）治疗 COVID-19 相关急性呼吸窘迫综合征（ARDS）：病例系列。
J Thromb Haemost. 2020 Jul;18(7):1752-1755. doi: 10.1111/jth.14828. Epub 2020 May 11.
5
D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis.D-二聚体与2019冠状病毒病的严重程度相关：一项汇总分析。
Thromb Haemost. 2020 May;120(5):876-878. doi: 10.1055/s-0040-1709650. Epub 2020 Apr 3.
6
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
7
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征：回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.2019年冠状病毒病（COVID-19）重症患者的降钙素原：一项荟萃分析。
Clin Chim Acta. 2020 Jun;505:190-191. doi: 10.1016/j.cca.2020.03.004. Epub 2020 Mar 4.
10
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.全长人血管紧张素转化酶 2 识别 SARS-CoV-2 的结构基础。
Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.
Zotero 插件